Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study.
Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study.
复制标题
DOI:
10.1371/journal.pone.0197148
复制
发表时间:
2018
期刊:
影响因子:
3.7
通讯作者:
Szuba A
中科院分区:
文献类型:
--
作者:
Chachaj A;Wiśniewski J;Rybka J;Butrym A;Biedroń M;Krzystek-Korpacka M;Fleszar MG;Karczewski M;Wróbel T;Mazur G;Gamian A;Szuba A
The study was designed to determine the associations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginines plasma concentrations with all-cause mortality in patients with hematological malignancies. 33 patients with acute myeloid leukemia (AML), 31 patients with non-Hodgkin’s lymphoma (nHL), 32 patients with chronic lymphocytic leukemia (CLL) and 48 patients without malignancy were enrolled into the study. Each patient was followed until death or for at least 14.5 months (range: 14.5–53). Median ADMA and SDMA were significantly elevated in AML, nHL and CLL compared to controls (ADMA: 1.36, 1.24, 1.03, 0.55 μmol/l respectively, p<0.0001; SDMA: 0.86, 0.76, 0.71, 0.52 μmol/l respectively, p<0.0001). High ADMA and SDMA were associated with increased risk for all-cause mortality in CLL group (Hazard ratio (HR) for ADMA: 3.05, 95% CI:1.58–5.88, p = 0.001; HR for SDMA: 4.71, 95% CI:1.91–11.58, p = 0.001). Our study suggests that ADMA and SDMA could be novel prognostic factors for all-cause mortality in CLL patients.
登录
查看更多内容
影响因子:
3.7
作者:
Cavalca V;Veglia F;Squellerio I;De Metrio M;Rubino M;Porro B;Moltrasio M;Tremoli E;Marenzi G
通讯作者:
Marenzi G
影响因子:
3.2
作者:
Choudhari SK;Chaudhary M;Bagde S;Gadbail AR;Joshi V
通讯作者:
Joshi V
影响因子:
7.3
作者:
Moncada, S;Higgs, EA
通讯作者:
Higgs, EA
影响因子:
3.7
作者:
Németh B;Ajtay Z;Hejjel L;Ferenci T;Ábrám Z;Murányi E;Kiss I
通讯作者:
Kiss I
DOI:
10.20452/pamw.1222
发表时间:
2012-01-01
影响因子:
--
作者:
Napora, Maria;Graczykowska, Anetta;Stompor, Tomasz
通讯作者:
Stompor, Tomasz